Navigation Links
Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
Date:9/13/2011

ng statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver including mNET, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We un
'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
2. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
3. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
4. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
5. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
8. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
9. Kuvan Receives Positive Opinion From CHMP for European Approval
10. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
11. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 05, 2015 RMI ... chronic orthopedic conditions such as meniscal tears, ACL ... and joint pain due to degenerative conditions like ... orthopedic surgeries to promote better post-surgical outcomes. , ... nearly pain-free bone marrow harvesting with two complimentary ...
(Date:3/4/2015)... USDM Life Sciences , a ... industry, hired David Blewitt as Vice President ... Services and Solutions at USDM Life Sciences , which ... maintaining compliance with government regulations worldwide. , For ... life sciences regulatory and IS compliance professional with extensive ...
(Date:3/4/2015)... 04, 2015 Proove Biosciences ... Medicine, is excited to announce the launch of ... Optimize the Management of Pain”. , The continuing ... for the next year. The focus of the ... recognize inadequate pain treatments, integrate appropriate pain management ...
(Date:3/4/2015)... Launched by the Assistance ... in December 2011, ,SARAH, - the French national ... sorafenib in advanced hepatocellular carcinoma (HCC) has enrolled more ... SARAH, a large French study of patients with ... has completed patient enrolment, exceeding its 400-patient target, according ...
Breaking Biology Technology:Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5
... (Amex:,SGN) has received its second Frost & Sullivan Technology ... at the Frost & Sullivan Awards Banquet,Signalife was awarded ... Patient Monitoring. Signalife,s Chief Executive Officer, Dr.,Lowell Harmison, and ... to accept the award., Signalife, Inc. is in ...
... 13 Sagent Pharmaceuticals,Inc., a privately-held specialty pharmaceutical ... injection, USP, an essential antibiotic,used to treat serious ... 1g single dose vials and 10g pharmacy bulk ... in the United States in 2006 were,approximately $69 ...
... ZURICH, Switzerland and FAIRFIELD, New Jersey, March 13, ... are uniquely positioned as the only biopharma company ... oral and,nasal delivery systems to administer the peptides. ... Upsher-Smith Laboratories, "Fortical" has,captured a near dominant 49% ...
Cached Biology Technology:Signalife Wins Second Frost & Sullivan Technology Award 2Signalife Wins Second Frost & Sullivan Technology Award 3Sagent Pharmaceuticals Launches Cefazolin for Injection, USP 2Stonegate Report About Unigene Laboratories Inc. 2Stonegate Report About Unigene Laboratories Inc. 3Stonegate Report About Unigene Laboratories Inc. 4Stonegate Report About Unigene Laboratories Inc. 5Stonegate Report About Unigene Laboratories Inc. 6Stonegate Report About Unigene Laboratories Inc. 7Stonegate Report About Unigene Laboratories Inc. 8Stonegate Report About Unigene Laboratories Inc. 9Stonegate Report About Unigene Laboratories Inc. 10
(Date:2/25/2015)... 25, 2015  ABC Financial Services (ABC), the ... Health and Fitness Industry, today announced enhancements to ... The latest upgrade includes advances to the agreement ... check-in via Identity One fingerprint biometrics. The features ... interactive displays at the International Health, Racquet & ...
(Date:2/19/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ) ... Electro-Optical / Infrared Systems Market by Type, by ... to 2020" report to their offering. ... expected to reach $16.35 billion by 2020, to ... report segments the military electro-optical/infrared systems market on ...
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... The increase in temperature in the Arctic has already caused ... the University of Gothenburg, Sweden, if the Arctic tundra also ... the rivers straight into the Arctic Ocean, resulting in additional ... the Arctic Ocean particularly in the Laptev Sea north of ...
... DC (January 8, 2010) Based on a comprehensive ... a group of the nation,s leading environmental scientists are ... U.S Army Corps of Engineers to stay all new ... Science , they argue that peer-reviewed research unequivocally ...
... rare disorder known as tuberous sclerosis complex (TSC), researchers ... of evidence suggesting that autism spectrum disorders, which affect ... a miswiring of connections in the developing brain, leading ... explain why many people with TSC have seizures and ...
Cached Biology News:Eminent group of scientists call for moratorium on issuance of mountaintop mining permits 2Eminent group of scientists call for moratorium on issuance of mountaintop mining permits 3Research adds to evidence that autism is a brain 'connectivity' disorder 2Research adds to evidence that autism is a brain 'connectivity' disorder 3
...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
... Components: MBP Coated ... Assay Dilution Buffer, 5X, #20 Magnesium/ATP Cocktail, ... Buffer, 10X LumiGLO™ Chemiluminescen LumiGLO™ Chemiluminescen ... enzyme assay Quality Assurance: ...
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
Biology Products: